发明名称 |
polipeptídeo modificado, composição aquosa, conjugado, polinucleotídeo, trímero, vetor de expressão, célula hospedeira, composição antigênica ou imunogênica, preparação farmacêutica, uso de pelo menos um polipeptídeo, e método de tratamento e/ou profilaxia contra uma infecção por iv. |
摘要 |
The present invention deals with a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41 (N), a C-helix region of gp41 (C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2 (IL2). |
申请公布号 |
BRPI1008671(A2) |
申请公布日期 |
2016.03.08 |
申请号 |
BR2010PI08671 |
申请日期 |
2010.02.08 |
申请人 |
MYMETICS CORPORATION |
发明人 |
NICOLAS MOUZ;ROGER,MARIE-GAELLE;SYLVAIN FLEURY |
分类号 |
A61K39/21;C07K14/16 |
主分类号 |
A61K39/21 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|